Sprout’s Female Desire Drug: Size Of Safety Studies Doesn’t Matter To FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Flibanserin development can move forward after dispute resolution, but women’s health advocates criticize the delay, charging that FDA has a double standard for female sexual dysfunction drugs.